DrugPatentWatch Database Preview
Canakinumab - Biologic Drug Details
» See Plans and Pricing
Summary for canakinumab
| Tradenames: | 1 |
| Patents: | 30 |
| Applicants: | 1 |
| BLAs: | 1 |
| Suppliers: see list | 1 |
| Recent Clinical Trials: | See clinical trials for canakinumab |
Recent Clinical Trials for canakinumab
Identify potential brand extensions & biosimilar entrants
| Sponsor | Phase |
|---|---|
| Pancreatic Cancer Action Network | Phase 1 |
| Swiss National Science Foundation | Phase 3 |
| University Hospital, Basel, Switzerland | Phase 3 |
Patent Text Search: US Patents for canakinumab
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis Pharms | ILARIS | canakinumab | INJECTABLE; SUBCUTANEOUS | 125319 | 001 | 2009-06-17 | Start Trial | City of Hope (Duarte, CA) | 2030-10-08 | RX | Orphan | search |
| Novartis Pharms | ILARIS | canakinumab | INJECTABLE; SUBCUTANEOUS | 125319 | 001 | 2009-06-17 | Start Trial | CONFLUENCE LIFE SCIENCES, INC. (St. Louis, MO) | 2039-02-26 | RX | Orphan | search |
| Novartis Pharms | ILARIS | canakinumab | INJECTABLE; SUBCUTANEOUS | 125319 | 001 | 2009-06-17 | Start Trial | SynChem, Inc. (Elk Grove Village, IL) | 2032-05-31 | RX | Orphan | search |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patents for canakinumab
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| China | 107840888 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2013120497 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2013055404 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
